Kyntra Bio
KYNB
150 hedge funds and large institutions have $747M invested in Kyntra Bio in 2022 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 51 increasing their positions, 51 reducing their positions, and 20 closing their positions.
655% more call options, than puts
Call options by funds: $21.6M | Put options by funds: $2.86M
0.11% more ownership
Funds ownership: 2.92% → 3.03% (+0.11%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 51
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
4% less funds holding
Funds holding: 156 → 150 (-6)
9% less capital invested
Capital invested by funds: $817M → $747M (-$69.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$41.8M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$7.65M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$6.17M |
| 4 |
Citigroup
New York
|
+$4.41M |
| 5 |
Jane Street
New York
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$14.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.83M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.79M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.38M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$4.32M |
KYNB Hedge Fund Activity: Q2 2022 in Review
150 of the 5,958 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q2 2022, worth a combined $747M — down 8.5% from $817M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of KYNB and 19 opened new positions — a net loss of 1 holder — while 51 trimmed existing stakes and 51 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $41.8M. The largest seller was Federated Hermes, cutting an estimated $14.5M.
- 150 institutional investors held Kyntra Bio (KYNB) as of Q2 2022, down from 156 in Q1 2022.
- Funds reported $747M of Kyntra Bio stock for Q2 2022, down 8.5% quarter-over-quarter.
- 19 funds opened new Kyntra Bio positions in Q2 2022 and 20 closed out, a net change of -1 holder.
- The largest Kyntra Bio buyer in Q2 2022 was Armistice Capital, an estimated $41.8M added.
- The largest Kyntra Bio seller in Q2 2022 was Federated Hermes, an estimated $14.5M sold.
Based on aggregated 13F filings for Q2 2022.